Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022

Empire Screen Highlights Wide Range of Warning, Danger, and Safety Decals

Colossal Biosciences Spins Out Form Bio to Revolutionize Computational Life Sciences

Form Bio's vision is to empower life scientists with a software platform for managing large datasets, executing verified workflows, visualizing results and collaborating with their peers. The platform brings these capabilities together in one cohesive unit with a user experience designed to simplify computational work and bolster life science breakthroughs across companies, labs and universities.

Biopharma PEG Offers GMP & Non-GMP Grade PEG Derivatives Manufacture Services

Huateng Pharma Develops Sitagliptin & Linagliptin Anti-diabetic Intermediates

VisualDx Partners with American College of Emergency Physicians to Build Library of Monkeypox Images Global Leader in Web-Based Clinical Decision Support to Launch Monkeypox Emergency Medicine Project to Help Clinicians with Diagnosis and Treatment

Bally Ribbon Mills Offers Custom-Designed Woven Materials for Critical Rigging and Tie Down Applications

Monon Bioventures receives nearly $400,000 to develop Purdue-discovered glioblastoma treatment

Monon Bioventure receives funding to develop Purdue-discovered glioblastoma treatment

Samsung Biologics Earns Gold Rating from EcoVadis for Its Sustainability Efforts

Alfa Chemistry Offers Abundant Choices of Alternative Energy Materials for Energy Storage & Batteries

Quanticate partners with Cancer Research UK to launch DETERMINE Study

Vyasa Adds Real-Time Dashboards to Layar Data Fabric

Vyasa, an innovative provider of highly scalable deep learning A.I. analytics software for healthcare, life sciences and business applications, today introduces its latest application interface, Signal. Featuring an intuitive design, Signal enables users to monitor trends and identify anomalies in their Layar data fabric through highly-visual charts and graphs delivered in a single dashboard.

Bora Pharmaceuticals partners with TaiRx, Inc. to manufacture breakthrough anticancer drug

Integrated DNA Technologies Launches New PrimeTime™ qPCR One-Step Master Mix with Exclusive Mutant Enzyme

BioIVT Acquires Fidelis Research

This transaction increases BioIVT's global network for collecting high-quality, disease-state biospecimens and extends its capabilities to deliver fresh biospecimens and produce cell products for drug and diagnostic development.

Abzena strengthens R&D capabilities to support rapid antibody discovery

For further information, images, and interview opportunities, please contact Kristy Harmer at ramarketing: kristy.harmer@ramarketingpr.com | +44 (0)191 222 1242 | ramarketingpr.com | Twitter: @ramarketingpr | Facebook: /ramarketingpr | Linkedin: /ramarketing About Abzena Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com.

Zebrafish Disease Models: Accelerating Human Disease Studies and Biomedical Research

Microbiosci Offers Real-time PCR Kits to Support Research Applications in Viral Detection

CRISPR/Cas9 Platform Provides Accurate Gene Knockout Mouse Models for Immunology Research and Drug Discovery

DDA Platform Offers A Wide Range of in Vitro and in Vivo Assays to Cover Early Stage Drug Discovery